Large-Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery Drives Drug Development

In this session, Sapient’s Founder and CEO Dr. Mo Jain discusses a next-generation, high throughput mass spectrometry-based platform that enables rapid population-level discovery of circulating biomarkers. He further highlights a series of real-world case studies in which these technologies have been applied to identify sensitive and specific biomarkers of biological processes, disease progression, and drug responsiveness to advance and accelerate drug development pipelines.